On June 17, the biotechnology company PrecisioBiotix Therapeutics, Inc. (referred to as Precisio) announced that it has received funding from the Gates Foundation to develop new engineered lytic enzyme antimicrobials targeting pathogenic symbionts associated with bacterial vaginosis (BV).
With the support of the Gates Foundation, Precisio will use its proprietary AI/ML-guided Zeus-LysiThru platform technology to discover engineered lytic enzymes with high activity and specificity. Lytic enzymes are a promising new class of enzyme formulations (based on cell wall lytic enzymes) that are precise, fast-acting, capable of clearing biofilms, and most importantly, unlike traditional chemical antibiotics, they are less likely to induce bacterial resistance.
The research work, supported by the Gates Foundation, aims to discover engineered lytic enzymes that are highly active against the main bacterial pathogens causing bacterial vaginosis (BV). Precisio is an American biotechnology company that has been deeply involved in China for many years, dedicated to developing pathogen-specific lytic enzyme biomedicines and antimicrobial agents through computer protein design and related high-tech platforms.
The founder and CEO
